Francis S. Markland

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.
Schönthal AH, Swenson SD, Chen TC, et al. (2020) Preclinical studies of a novel snake venom-derived recombinant disintegrin with antitumor activity: A review. Biochemical Pharmacology. 114149
Swenson SD, Silva-Hirschberg C, Markland FS. (2020) Methods for Evaluation of a Snake Venom-Derived Disintegrin in Animal Models of Human Cancer. Methods in Molecular Biology (Clifton, N.J.). 2068: 185-204
Swenson S, Minea RO, Tuan CD, et al. (2018) A Novel Venom-Derived Peptide for Brachytherapy of Glioblastoma: Preclinical Studies in Mice. Molecules (Basel, Switzerland). 23
Swenson S, Minea R, Moore J, et al. (2015) Abstract POSTER-THER-1432: Intraperitoneal delivery of the disintegrin vicrostatin (VCN) effectively limits ovarian cancer growth and progression Clinical Cancer Research. 21
Janib SM, Gustafson JA, Minea RO, et al. (2014) Multimeric disintegrin protein polymer fusions that target tumor vasculature. Biomacromolecules. 15: 2347-58
Minea R, Helchowski C, Rubino B, et al. (2012) Development of a chimeric recombinant disintegrin as a cost-effective anti-cancer agent with promising translational potential. Toxicon : Official Journal of the International Society On Toxinology. 59: 472-86
Markland FS, Pinski J, Swenson S, et al. (2012) Abstract A14: A novel integrin-targeted therapeutic agent for prostate cancer with anti-tumor/anti-angiogenic activity Cancer Research. 72: A14-A14
Swenson SD, Li Z, Minea R, et al. (2012) Abstract 5248: A novel ovarian cancer imaging agent based on integrin ligation Cancer Research. 72: 5248-5248
Swenson S, Minea R, Zidovetzki S, et al. (2011) Anti-angiogenesis and disintegrins Toxins and Hemostasis: From Bench to Bedside. 301-329
Markland FS, Swenson S. (2010) Fibrolase: trials and tribulations. Toxins. 2: 793-808